

Allen & Hanburys Limited
(Registered Number 40209)

Annual Report and Financial Statements

For the year ended 31st December 2010

FRIDAY



ADL5KRD1

A41

04/02/2011

358

COMPANIES HOUSE

Registered office address:

Glaxo Wellcome House
Berkeley Avenue
Greenford
Middlesex
UB6 0NN
England

Allen & Hanburys Limited

Annual Report and Financial Statements

For the year ended 31st December 2010

	Pages
Directors' Report	1-2
Balance Sheet	3
Notes to the Financial Statements	4-5

Allen & Hanburys Limited
(Registered Number 40209)

Directors' Report for the year ended 31st December 2010

The Directors submit their report and the financial statements for the year ended 31st December 2010

Principal activities

The Company did not trade during the period. There was no transfer to reserves for the year (2009 - £nil)

Directors and their interests

The Directors of the Company who served during the year are as follows

Edinburgh Pharmaceutical Industries Limited
Glaxo Group Limited
A Grist - Resigned 20/10/ 2010
D Davies - Appointed 16/08/ 2010

No Director had, during the year or at the end of the year, any material interest in any contract of significance to the Company's business with the exception of the Corporate Directors, where such an interest may arise in the ordinary course of business

Directors' Indemnity

Each of the Directors benefits from an indemnity given by the Company under its articles of association. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of his, her or its duties.

Statement of Directors' Responsibilities in respect of the Annual Report and the financial statements

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing those financial statements, the Directors are required to

- Select suitable accounting policies and then apply them consistently,
- Make judgements and estimates that are reasonable and prudent,
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business, in which case there should be supporting assumptions or qualifications as necessary.

The Directors confirm that they have complied with the above requirements in preparing the

Allen & Hanburys Limited
(Registered Number 40209)

Directors' Report for the year ended 31st December 2010

financial statements

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent auditors

The Company, having not traded during the year, satisfied the conditions for exemption from audit as specified in Section 480 of the Companies Act 2006 for the year ended 31st December 2010.

This report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

By order of the Board



P Williamson
For and on behalf of Edinburgh Pharmaceutical Industries Limited
Director
19 January 2011

Allen & Hanburys Limited

Balance Sheet

As at 31st December 2010

	Note	2010 £	2009 £
Current assets			
Debtors	2	2,629,540	2,629,540
Net assets		2,629,540	2,629,540
Capital and reserves			
Called up share capital	3	963,400	963,400
Share premium account	4	410,000	410,000
Profit and loss account	4	1,256,140	1,256,140
Total shareholders' funds	5	2,629,540	2,629,540

During the financial year and the preceding financial year the Company undertook no significant accounting transactions. Consequently the Company made neither a profit, a loss nor any other recognised gains and losses during the year and therefore has not prepared a profit and loss account or a separate statement of total recognised gains and losses.

For the year ending 31st December 2010 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' Responsibilities

- The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476, and
- The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The accounts on pages 3 to 5 were approved by the Board of Directors on 19 January 2011 and were signed on its behalf by:



P Williamson

For and on behalf of Edinburgh Pharmaceutical Industries Limited – Director

The notes on pages 4 to 5 form part of these financial statements

Allen & Hanburys Limited

Notes to the Financial Statements for the year ended 31st December 2010

1 Accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below

a) Basis of accounting

These financial statements have been prepared under the historical cost convention, the accounting policies set out below, which have been applied consistently, and in accordance with the Companies Act 2006 and applicable UK Accounting Standards

b) Debtors

Debtors represent intercompany balances with other GlaxoSmithKline Group (the "Group") undertakings and accordingly are valued in line with the corresponding agreements

2 Debtors

	2010 £	2009 £
Falling due after one year		
Amounts owed by parent undertaking	2,629,540	2,629,540

3 Called up share capital – equity interests

	2010 Number of shares	2009 Number of shares	2010 £	2009 £
Authorised				
Equity shares				
Ordinary shares of £1 each	1,000,000	1,000,000	1,000,000	1,000,000
Allotted, issued and fully paid				
Equity shares				
Ordinary shares of £1 each	963,400	963,400	963,400	963,400

4 Reserves

	Profit and loss account £	Share premium account £	Total reserves £
As at 1st January 2010 and 31st December 2010	1,256,140	410,000	1,666,140

5 Reconciliation of movement in shareholders' funds

	2010 £	2009 £
Opening and closing shareholders' funds	2,629,540	2,629,540

Allen & Hanburys Limited

Notes to the Financial Statements for the year ended 31st December 2010

6 Directors' remuneration

During the year the Directors of the Company, with the exception of the Corporate Directors, were remunerated as executives of the Group and received no remuneration in respect of their services to the Company (2009 - £nil) Corporate Directors received no remuneration during the year, either as executives of the Group or in respect of their services to the Company (2009 - £nil)

7 Employee information

The Company has no employees as all personnel are employed by other Group companies (2009 - nil)

8 Cash flow statement

A cash flow statement has been included in the consolidated financial statements of GlaxoSmithKline plc, the ultimate parent undertaking, which are publicly available. As a wholly owned subsidiary of the ultimate parent undertaking, advantage has been taken of the exemption afforded by FRS 1 'Cash Flow Statements' (Revised 1996) not to prepare a cash flow statement.

9 Ultimate parent undertaking

GlaxoSmithKline plc, a company registered in England and Wales, is the Company's ultimate parent undertaking and controlling party. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company, are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated financial statements can be obtained from The Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS. The immediate parent undertaking is Glaxo Wellcome UK Limited.

10 Related party transactions

As a wholly owned subsidiary of the ultimate parent company, GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 8 'Related Party Disclosures' not to disclose any related party transactions within the Group. There are no other related party transactions.